Literature DB >> 16303004

Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients.

R Y Gohh1, A F Yango, P E Morrissey, A P Monaco, A Gautam, M Sharma, E T McCarthy, V J Savin.   

Abstract

Recurrent focal segmental glomerulosclerosis (FSGS) following transplantation is ascribed to the presence of a circulating FSGS permeability factor (FSPF). Plasmapheresis (PP) can induce remission of proteinuria in recurrent FSGS. This study addressed the efficacy of pre-transplant PP in decreasing the incidence of recurrence in high-risk patients. Ten patients at high-risk for FSGS recurrence because of rapid progression to renal failure (n = 4) or prior transplant recurrence of FSGS (n = 6) underwent a course of 8 PP treatments in the peri-operative period. Recurrences were identified by proteinuria >3 g/day and confirmed by biopsy. Seven patients, including all 4 with first grafts and 3 of 6 with prior recurrence, were free of recurrence at follow-up (238-1258 days). Final serum creatinine in 8 patients with functioning kidneys averaged 1.53 mg/dL. FSGS recurred within 3 months in 3 patients, each of whom had lost prior transplants to recurrent FSGS. Two of these progressed to end-stage renal disease (ESRD) and the third has significant renal dysfunction. Based on inclusion criteria, recurrence rates of 60% were expected if no treatment was given. Therefore, PP may decrease the incidence of recurrent FSGS in high-risk patients. Definitive conclusions regarding optimal management can only be drawn from larger, randomized, controlled studies.

Entities:  

Mesh:

Year:  2005        PMID: 16303004     DOI: 10.1111/j.1600-6143.2005.01112.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  45 in total

Review 1.  Target organ damage in African American hypertension: role of APOL1.

Authors:  Barry I Freedman; Mariana Murea
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

Review 2.  Principles of separation: indications and therapeutic targets for plasma exchange.

Authors:  Mark E Williams; Rasheed A Balogun
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

Review 3.  Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.

Authors:  Caitlin E Carter; Nadine M Benador
Journal:  Pediatr Nephrol       Date:  2013-06-29       Impact factor: 3.714

4.  The APOL1 gene and allograft survival after kidney transplantation.

Authors:  A M Reeves-Daniel; J A DePalma; A J Bleyer; M V Rocco; M Murea; P L Adams; C D Langefeld; D W Bowden; P J Hicks; R J Stratta; J-J Lin; D F Kiger; M D Gautreaux; J Divers; B I Freedman
Journal:  Am J Transplant       Date:  2011-04-12       Impact factor: 8.086

Review 5.  Update on the treatment of focal segmental glomerulosclerosis in renal transplantation.

Authors:  Maria Messina; Ester Gallo; Alberto Mella; Fabiola Pagani; Luigi Biancone
Journal:  World J Transplant       Date:  2016-03-24

Review 6.  Extrarenal determinants of kidney filter function.

Authors:  Eunsil Hahm; Vasil Peev; Jochen Reiser
Journal:  Cell Tissue Res       Date:  2017-05-30       Impact factor: 5.249

Review 7.  Recent progress in the pathophysiology and treatment of FSGS recurrence.

Authors:  P Cravedi; J B Kopp; G Remuzzi
Journal:  Am J Transplant       Date:  2013-01-11       Impact factor: 8.086

Review 8.  Rituximab therapy in nephrotic syndrome: implications for patients' management.

Authors:  Aditi Sinha; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2013-01-22       Impact factor: 28.314

Review 9.  Advances in apheresis therapy for glomerular diseases.

Authors:  Hitoshi Yokoyama; Takashi Wada; Wei Zhang; Hideki Yamaya; Mitsuhiro Asaka
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

Review 10.  Disease recurrence in paediatric renal transplantation.

Authors:  Pierre Cochat; Sonia Fargue; Guillaume Mestrallet; Therese Jungraithmayr; Paulo Koch-Nogueira; Bruno Ranchin; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2009-02-27       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.